Phage and Yeast Display
Curia offers phage and eukaryotic-based yeast display platforms for in vitro discovery and engineering of potent antibody candidates for therapeutic or diagnostic use. High-affinity functional antibodies are routinely selected against a wide range of conventional or challenging targets (e.g. GPCRs) using customized or in-licensed state-of-the-art libraries. Multiple antibody scaffolds (llama VHH, scFv, Fab, reformatted IgG) can be delivered upon request. Curia’s unparalleled in vitro antibody discovery capabilities can be bundled with unique lead optimization, characterization, and downstream large-scale GMP production, therefore providing the entire spectrum of early to late-stage antibody-drug generation services.
Comprehensive service includes:
- Strategy design
- Access to naïve (including XOMA031 and XOMA040 libraries with a full human repertoire), semi-synthetic, or immune libraries of scFvs, Fabs or llama VHH and custom library screening.
- Primary and secondary functional screens (multiple hits)
- Lead antibody characterizations:
- Kinetics and epitope binning using Octet® or Carterra® LSA
- Ligand blocking
- ELISA
- Cell assays
Curia’s Phage Display Antibody Discovery Services
| Strategy Design | Library Construction | Screening and Selection | 1 or 2 degree Functional Screens | Lead Antibody Characterization |
|---|---|---|---|---|
| – Flexible workflow – Parallel campaigns | – Large and diverse – Different antibody scaffolds | – Immobilized, cell, or soluble antigens – ELISA/FACS binding – Preliminary kinetics | – Cell-based assays – Reporter assays – Neutralization assays | – lgG reformatting – Kinetics & epitope binning – Ligand blocking |
Antibody Discovery & Engineering Services
The Curia Antibody Center offers comprehensive antibody discovery and engineering services, including identification, optimization, and characterization of new leads.